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ABSTRACT 
M alignant hyperthermia (MH) is a rare pharmacogenetic disorder in humans caused by 
inhalational general anaesthetics and depolarising muscle relaxants. An MH reaction 
shows abnormal calcium homeostasis in skeletal muscle lead ing to a hypermetabolic 
state and increased muscle contracture. A mutation w ithin the calcium release channel 
ryanodine receptor of. keletal muscle (RYR I) is one of the causes o f MH leading to the 
abnormally high release of calcium ions into the cytosol during MH reactions. 
The MH reaction can also be triggered by excess exercise. heat and stress. A New 
Zealand male. ident ified as M 8 I 8, showed a fulminant MH reaction wh ich resulted in 
death. The reaction was caused by exerci. e. and he did not have a fami ly history of MH. 
As this indi vidual did not have any o f the mutations within RYR I found 10 date in New 
Zealand famil ies. the entire RYRI cDNA was screened for a novel mutation that may 
result in susceptibi lity to exercise- induced MH. This patient may have had a novel 
RYR I mutation because exercise- induced MH is qui te rare. Screening of this gene. 
however did not identify any mutations within RYR I, suggesting that the M 8 18 pat ient 
may have a mutation in another gene because Ml-I is a heterogeneous disorder w ith 
40-50% of fam ilies showing linkage to alternati ve loci. 
Heterogeneity of M H can re. ult in discordance between genotype and phenotype. Some 
Ml-I susceptible patients do not have a RYR I mutation that is found in other indi viduals 
w ith the same kindred. One or more other genes could be associated with M H for these 
individuals al though alternati ve loc i have not been studied in New Zealand fami lies. A 
genome-wide scan was performed to search for other candidate loc i using a large M l-I 
k indred known as the CH fami ly w ithin which discordance has been observed. 
Non-parametric linkage analysis across all chromosomes identified fi ve weak l inkages 
from one branch, and two strong linkages from another branch of the CH family. 
Secondary linkage analysis was performed on one cand idate locus identified in the 
genome-wide scan, and a weak linkage and recombination was observed within the 
shorter region. No candidate genes with obvious relevance to calcium homeostasis or 
signalling were identified w ithin this region. The existence of alternative causati ve loc i 
in this fami ly cannot be ruled out however, because the loci identified from the 
genome-w ide scan are very large and contain many genes of unknown function. 
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CHAPTER ONE INTRODUCTION 
1.1 Overview of Malignant Hyperthermia 
1.1.1 Introduction 
Mali gnant Hyperthermia (MH) is an autosomal dominant inherited di sorder of the 
skeletal musc le in humans as well as in diffe rent animals and is tri ggered by vo latil e 
anaes theti cs and depolari s ing muscle relaxants used in general anaes thes ia . MH leads to 
a hypermetaboli c state and an abnormall y high release of calcium ions from the 
sarcoplasmic reticulum of skeletal musc le ( I ). Palmerston North Hospi tal is the sole 
M H testing centre in New Zealand and also maintains a database of MH reactions and 
affected famili es . The inc idence of MH is much higher in the lower North Island than 
o ther areas wo rl dwide because there are some large famil ies known to have the disorder. 
O ne patient wi ll be d iagnosed and treated as MH suscepti ble fo r every 100 pati ents in 
general surgery at Palmerston North Hosp ita l (2). To date, about 40 famili es have been 
confirmed as M H susceptib le in ew Zea land fro m cl inica l reacti ons or in vitro 
contracture tes ting. 
1.1. 2 History 
Inex plicable deaths and abnormal reacti ons during operations or in a postoperati ve stage 
were reported in the earl y 1900s. In 1960, it was reported that anaes theti c could cause 
hype rthermja and even death in several families (3) . The di sorder was found to be 
hereditary and the result of a dominant trait (4). Several years later, it was observed that 
individuals who had recovered from MH showed higher muscle contrac ture against 
halothane and caffeine in an in vitro test (5, 6). From these observations, the European 
MH Group developed a protocol of di agnostic testing using muscle specimens (7). The 
North American MH Group also developed a test protocol differing onl y in minor 
aspects (8). These protocols are still used today as the "gold standard" diagnostic tests 
fo r MH. The incidence of MH on a worldwide scale has been estimated to be 1: 15,000 
anaes thetics fo r children and 1 :50,000 fo r adults (9). In the 1970s, two-thirds of affected 
patients died during or as a result of anaesthesia, usuall y from cardi ac arrest. Dantrolene 
sodium was introduced as an antidote for MH in 1979 (10) and as a result, mortality has 
dropped to less than 5 % today (11). 
1.1.3 Clinical symptoms 
Establishing the diagnosis of MH by clinical signs is difficult because none of the 
clinical symptoms can be regarded as spec ific signs of MH (12). MH reactions have 
vari able intensity and time course. General signs observed from MH reactions include 
tachycardia, respiratory or metabolic acidosi s, masseter spasm, generali sed muscular 
ri g idity, arrh ythmias, rhabdomyolysis, skin mottling, and rapid temperature elevation 
( 13, 14). Attempts have been made to predict MH susceptibility by observing these 
clinical indicators (15), however MH reactions can develop slowly, even in a 
postoperative onset without any clinical signs during the operation (16). Furthermore, 
some case reports have shown that MH susceptible individuals do not always show 
ab normal reactions against tri ggerin g drugs (17). These atypical forms of MH reactions 
may delay anaes theti sts in establi shing diagnoses and treatments of MH. Nevertheless, a 
clinical grad ing scale has been established to evaluate MH-like symptoms and is used to 
assess the relati vely likelihood of clinical symptoms actuall y being MH (15). 
1.1.4 Triggering agents 
MH reactions can be tri ggered by anaes thetics widely used in general anaes thes ia . 
These inc lude non-halogenated anaes thetics such as ether and halogenated ones such as 
halothane, sevoflurane and desflurane ( 18). Halothane seems to be the most potent 
tri gger. Depolarising muscle relaxants such as succinylcholine also induce MH although 
it has been reported that pure succinylcholine itself does not induce muscle contraction 
( 19). Commercial succinylcholine solutions contain cresol derivati ves such as 
4-chloro-m-cresol (4-CmC) as a preservative, and it is thought that 4-CmC itself can be 
a trigger of MH reactions (20, 21). Chlorocresol derivatives are routinely added to 
commercial drugs as preservatives, and these drugs should not be used for MH 
susceptible patients. Some case reports have shown that psychotropic substances or 
tranquillisers like phenothiazines and tricyclic antidepressants may be tri ggers of MH 
although this is still controversial because of a low number of case reports (22, 23). 
These drugs should not be given to MH patients because they may induce symptoms 
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similar to MH and may hamper the establi shment of a clinical diagnosis of MH. 
Non-anaesthetic factors can also induce MH reactions. Exercise before the 
admini stration of a triggering agent increases the incidence and intensity of MH (24), 
and overheating alone can tri gger MH reactions in swine (25). In fact, some case studies 
have reported MH reactions related to heat stroke in humans (26 , 27). Some MH 
susceptible individuals show an abnormal response to graded exerci se (28), and it has 
been confirmed that strenuous exercise can tri gger MH in some individual s (29). Mental 
excitement may increase the intensity of reactions against drugs (30) and variance of 
intensity has been observed in an anxious patient (3 1 ). Hence, it has been suggested that 
MH may be a human stress syndrome (32) . Overheating caused by viral in fec ti on has 
also been reported to induce MH (33). 
1.1 .5 Management and treatment 
Any tri ggering anaes thetics should be avo ided fo r MH susceptible indi viduals during 
anaes thesia. There are some su itable dru gs for patients (34), and the non-tri ggering 
anaes thetic. propofol, is often used today for MH susceptibl e individuals. It is a 
non-water-soluble intravenous agent that does not tri gger MH reactions (35) . If MH 
reacti ons occur, it is critical to es tab li sh the diagnosis and terminate the ad mini stration 
of triggering dru gs immediately. Dantrolene sodium is very effect ive in an MH reaction 
by preventing a hypermetabo li c state. Immersion in an ice-cold bath is also effective for 
fulminant hyperthermi a. Patients who suffer an MH reaction should be treated in an 
intensive care unit with body temperature and pul se being monitored. Patients who 
recover from MH, however may suffer sequeli such as muscle di sability from 
rhabdomyolys is or impaired function of major organs (5). 
1.2 Pathophysiology of MH 
1.2.1 Introduction 
Although the exact mechanism of variable MH reactions is not understood, malfunction 
of intracellular Ca2+ homeostasis has been shown to play an important role (36). MH 
susceptible individuals show higher concentrations of cytosolic Ca2+ during MH 
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reactions and also in normal conditions wi thout exposure to triggering drugs (37). In 
addition, an abnormal sarcoplasmic reticulum (SR) ryanodine receptor in the skeletal 
muscle has been reported to be responsible for the abnormal calcium release in -50% of 
affected fami I ies (38). 
1.2.2 Excitation-contraction coupling 
fntracellular Ca2+ regulates a wide range of events in all cel ls, such as cell growth, 
mitochondri al function, gene expression and mu cle contraction. Ca2+ plays a 
fundamental role in excitation-contraction (EC) coupling of skeletal muscles (39). The 
wave of depolarisation from nerves is detected by an L-type voltage-dependent ca2+ 
channel called the dihydropyrid ine receptor (DHPR) located in the wall of the 
transverse tubule (T-tubule). DHPR transmits the signal to the funct ionally coupled 
calcium release channel. ryanodine receptor (RYR). and acti vates it to release Ca2+ from 
the SR to intracellular cytosol (Figure 1- 1 ). The released Ca2+ binds to troponin and 
activates actin. and muscle contraction occurs. The intracellular free Ca2+ is rapidly 
transferred back to the SR by ATP-ase calcium pumps and stored within the lumen, and 
muscle relaxation occurs (40). 
1.2.3 Dihydropyridine receptor 
The DHPR is located in the T-tubule membrane and detects membrane depolarisation. It 
is an L-type calcium channel passi ng Ca2+ through to the cytoplasm. It is also a voltage 
sensor, and if it detects a s ignal from nerves, it tra nsmits the signal to the RYR leading it 
to open and releasing Ca2+ from the SR. The DHPR is an asymmetric protein which 
consists of five subunits (4 1) (Figure 1-1). The al-subunit (185 kDa) consists of fou r 
domains I to IV and is located in the T-tubule membrane (42). This subunit contains 
positive charges and senses plasma membrane depolari sation. It complexes with a 
cytoplasmic subunit (~, 54 kDa) and two intra membrane subunits (y, 30 kDa and 8, 26 
kDa). An extracellular subunit (a2, 143 kDa) is linked via a di sulfide bridge to the 
8-subunit. The DHPR is clustered with the T-tubule and RYR forming the triad, and the 
signal is transmitted through the loop between the II and III domains to the RYR (Figure 
I - ! ), controlling release of Ca2+ and following EC coupling via the RYR (43). The 
activated RYR also transmits a current-enhancing signal to the DHPR through the II-Ill 
4 
loop (44). 
Dihydropyridine Receptor 
IV 
Ill 
II 
0 extracellular 
(t' I r 
cytoplasm /3 
intracellular 
..J signal 
( ' ' a-
Ryanodine Receptor 
-
Ca2+-ATPase 
(';:;i"'' 
sarcoplasmic reticulum 
Figure 1-1 The excitation-contraction pathway of skeletal muscle 
A depolarising signal is received by the DHPR and transmitted to the RYR through 
the II-III loop causing a release of calcium ions from the SR. One DHPR and one of 
four monomers of RYR are shown. Other associated proteins are omitted. The released 
calcium ions are pumped back to the SR lumen by a calcium transport ATPase. Diagram 
adapted from references ( 45) and ( 46). 
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1.2.4 Ryanodine receptor 
The RYR is a large Ca2+ channel situated in the SR membrane (47) and is built up of 
four monomers, each with a molecular weight of about 560 kDa (48, 49). About 80 % of 
the protein is ex posed in the cytoplasm forming the foot structure (50), and the 
remaining carboxyl terminal (C-terminal ) region is embedded in the SR membrane 
(Figure 1- 1). The RYR receives the s igna l from the activated DHPR, and opens the 
channel releas ing Ca2+ from the SR lumen to cytoplasm. Three separate genes identified 
as RYRJ , RYR2 and RYRJ have been found to encode the RYR (5 1), and each is 
predominantl y ex pressed in ske letal musc le, cardi ac musc le or brain and smooth muscle, 
respectively (52-54) . 
1.2.5 The proposed mechanism of MH reactions 
As Ca2+ controls severa l important systems in cells, Ca2+ concentrations within the 
cytoplasm are under ti ght control. The act iva ted RYR has a very short open time and is 
regul ated by ATP, Mg2+ and Ca2+. In addition, re leased Ca2+ within the cytop las m is 
pumped back to the SR readil y by a Ca2+-ATPase (Figure 1-2. left). Hence, the 
metabolic state and musc le contracture do not las t long. In contrast, an MH c ri sis shows 
dysfunctional control of Ca2+ release. In musc le specimens from MH . usceptible swine, 
the RYR shows a prolo nged duration of the open state and has a defect in a low-affinity 
Ca2+ binding s ite (55). In addition , Ca2+ re lease in MH susceptible musc les is reduced 
far later than in normal spec imens (56). Hence, it is thought that the RYR does not c lose 
readil y during MH reactions allowing large amounts of Ca2+ to pass through to the 
cytoplasm. The re leased Ca2+ induces muscle contraction and mitochondrial metabolism 
(Figure 1-2, right). Excessive muscle contraction causes membrane damaoe leading to 
rhabdomyolysis , and the overall higher metabolic activity causes increased CO2 and 
heat production as well as increased 0 2 consumption leading to acidosis, tachycardia 
and hyperthermia. These events may cause death because of cardiac arrhythmia or 
cardiac arrest. 
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Figure 1-2 Proposed mechanism for induction of malignant hyperthermia 
The act ivated RYR re leases ca lcium ions from the SR 10 cyto. o l. Released intracellular 
Ca2+ within the muscle cell induces muscle contraction. The RYR close. immediately 
and Ca2+-ATPase pumps rapidly transfer unbound Ca2+ back into the SR. and 
normalised Ca2+ concentration results in muscle relaxation (left). In MHS muscle cell s, 
the RYR does not close read ily causing an abnormally high release of Ca2+ into the 
cytoplasm. Hence, excess ca lcium ions induce a hypermetabolic state and excess muscle 
contraction (right). From reference ( l ). 
1.3 Diagnosis of MH 
1.3.1 The in vitro contracture test 
As prediction of M H from cl inical signs 1s diffic ul t, attempts have been made to 
establish preoperati ve tests to diagnose MH suscepti bility, but un fortunately, they have 
lacked reliability (57). To date, the gold standard and widely used method is the in vitro 
contracture test (JVCT), which is a method to determine the response of a patient's 
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muscle to the triggering agents halothane and caffeine in vitro (5, 6). The IVCT requires 
the surgical exc ision of a piece of quadricep muscle to provide several muscle 
specimens for inves ti gation . The fresh specimens are suspended in a bath , and the test 
drugs, halothane or caffeine, are added. Tension of the muscle is measured by a 
transducer before and afte r addition of the drugs. 
T he E uropean MH Group developed a protocol fo r the IVCT in 1984. Thi s protocol 
defin es a pos iti ve response as 0.2 g or greater aga inst 2 % v/v halothane or 2.0 mM 
caffeine . If both tests using halothane and caffeine show pos iti ve responses, the 
individual is diagnosed as MH susceptibl e (MHS). If both tests do not show pos itive 
responses at all , then the diagnosis is MH norm al (MHN). If only the halothane tes t o r 
on ly the caffeine test is positive, then the diagnosis is MH equi vocal (M HE) a ltho ugh 
the person is regarded as c linica ll y susceptible to MH . The North American MH Group 
has a lso developed an IVCT protoco l in 1989 that differs s li ghtl y from the E uropean 
protoco l (8). lt defi nes 0.5 and 0.3 gas a pos iti ve response to 3 % v/v halothane and 2.0 
mM caffeine tes t, res pecti vely. The North Ameri can protoco l does not estab li sh an MHE 
diagnosis. If one or both drug tes ts ex hibit a positive response, then the diagnosis is MH 
positive (M H+), otherw ise the patient is considered negative for MH (M H-). Therefore, 
it has been sa id that the North American protocol cou ld result in more false positive or 
negat ive diagnoses than the European protoco l (58). 
1 .3.2 Limitation of the IVCT 
Unfortunately, the IVCT is not an abso lute method for di agnosis of MH. It has been 
reported that the E uropean protocol has 99 % sens iti vity and 93.6 % spec ific ity, and the 
North American protoco l has 97 % sensiti vity and 78 % specificity (59). This means 
that even the most reliable method , the European protocol, can produce l % false 
negative diagnoses and about 4 % false positive di agnoses. In fact, some cases of false 
negative diagnoses have already been reported (60 ). In addition, the IVCT is invasive 
and expensive, requiring minor surgery and temporary di sability as well as a degree of 
uncertainty in diagnosis due to the equivocal nature of the tes t itself as well as the 
possibility of obtaining insufficient tissue. Hence, refinements in testing protocols or 
other methods for testing are required (61). 
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1.3.3 Other diagnostic methods 
To improve reliability and discrimination between the MHS and MHN groups, the 
protocol for the IVCT has been modified with the introduction of drugs to replace or 
supplement halothane and ca ffeine. These include ryanodine, 4-chloro-m-cresol 
(4-CmC) and the phosphodiesterase-III inhibitor enoximone (62-64). 4-CmC may be a 
more reliable drug than halothane or caffeine. Multicentre evaluation has estimated its 
sensitivity and specificity as 96.1 % and 99 %. respecti vely (65). Other non-invasi ve 
diagnostic tests to replace the IVCT have also been developed. 
Galloway et al. (1984) introduced phosphorus-J I nuclear magnetic resonance (3 1p 
NMR) to determine relative concentrations of ATP, phosphocreatine (PCr) and inorganic 
phosphorus (Pi) in skeletal muscle (66). MHS muscle shows an abnormal metaboli c 
state against tri ggering drugs, and hence. shows significantly higher Pi/PCr values than 
does MHN muscle (67). This method is not currently used for diagnostic testing, 
however because the value is changeable, and it is not sufficiently reliable 10 estab lish 
diagnoses (68). A s abnormal Ca2+ release is an important phenomenon during MH 
reactions, Ca2+ release from the SR in skeletal muscle stimulated by drugs in 1·irro has 
been investigated. Cen. ier et al. ( 1998) found that cultured skeletal muscle cells from 
MHS indi viduals showed abnormal intracellular ca lcium homeostasis in the presence of 
halothane (69). Later, coincidence of diagnoses from this method and from the IVCT 
was reported (70). This method does not replace the IVCT however, because it does not 
have higher sensitivity or specificity than can be obtained w ith the IVCT. It also 
requires skeletal muscle for cell culture, and is thus invasive and time consuming 
although the procedure could be developed from skeletal musc le obtained from needle 
biopsy and hence would be less invasive for patients than surgical excision for the IVCT 
(7 I ). Klingler er al. (2002) have also introduced a diagnostic method using cu ltured 
skeletal muscle cells (72). These authors have determined H+ release instead of Ca2+ 
after the administration of 4-CmC, although this method requires an expensive 
microphysiometer to detect secretion from cultured cells. 
Blood samples have also been used to predict MH susceptibility. Anetseder et al. (2002) 
have introduced the in vivo caffeine test. After intramuscular injection of caffeine, MHS 
individuals show higher local carbon dioxide pressure (pCO2) because of the high 
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metabolic state caused by caffeine, but MHN individuals do not (73). Sei et al. (1999) 
have fou nd that RYRJ is not expressed onl y in skeletal muscle, but also in B 
lymphocytes (74). As the type l RYR plays a critical role for calcium signalling in B 
lymphocytes, it is thought that these cells wou ld show abnormal calcium homeostasis 
against drugs in MHS patients. In fact, a few reports have shown higher drug- induced 
Ca2+ re lease from MHS B lymphocytes iso lated from blood (75, 76). These techniques 
do not require muscle biopsy and have the possibility of replacing the IVCT, a lthough 
furth er investi gation is required to confirm reliability, sensitiv ity and spec ifi city. 
1.4 Other disorders associated with MH 
1.4.1 Central core disease 
MH may be assoc iated with other disorders espec ia ll y myopathy. So far, the onl y 
disease that is clearly assoc iated with MH is central core disease (CCD). CCD is a 
morphologicall y distinct myopathy with quite variab le c linical feat ures . It is 
characte ri sed by muscle weak ness and muscle cramps after exerc ise, and autosomal 
dominant inheritance is observed in most subj ects . The assoc iat ion of thi s ra re disorder 
with MH has been fo und from observation that most CCD patients have an abnormal 
response in the IVCT or show MH reactions during anaes thes ia indicati ng that the two 
disorders can co-exist (77) . Therefore, accordin g to these observations, a ll patients with 
CCD must be considered at risk from MH unless the IVCT indicates otherw ise. 
1.4.2 Other disorders 
Other di sorders may also be associated with MH although evidence of association has 
still not been shown conclusively. Kin g and Denborough (1973) reported an unusual 
syndrome within MHS patients in Austra li a and New Zealand (78). The syndrome, 
called King Syndrome is characterised by short stature, slowly progress ive myopathy 
and an unusual facia l appearance. The cause of the disease is unknown and the 
association with MH is still unclear, but some case reports have indicated co-existence 
of MH and King syndrome (79). Other myopathies including Duchenne muscular 
dystrophy, Evans myopathy and myoadenylate deaminase deficiency may have some 
relationship to MH (80) although this is still controversial. 
10 
The association of MH with sudden infant death syndrome (SIDS) has been indicated in 
the early 1980s because of the high rate of SIDS incidence within MHS famjJies (8 1, 
82). The cause and mechanism of SIDS is still unknown , but some reports have shown 
that overheati ng may be one of the causative factors (83, 84). MH can be triggered by 
overheating itself (25), and hence, it could be the cause of SIDS fo r some MHS infa nts. 
1.5 Animal models 
1.5.1 Porcine model 
The homologous disorder to human MH has been fo und in some animals. Porcine MH 
was reported in 1966 and has been widely inves ti gated as a model of human MH (85). It 
shows an autosomal recessive trait whereas human MH is au tosomal dominant (86) . 
Porcine MH is sometimes tri ggered by stress, such as fighting, and hi gh temperature 
(87). It is called porcine stress syndrome indicati ng that human MH may be a human 
stress syndrome. The skele tal SR from MHS pigs shows an abnorm al re lease of Ca2+ 
caused by halothane and caffeine (88, 89). In addit ion, linkage ana lysis has revealed that 
chromosome 6q is linked to the d isorder and the susceptible locus encodes the RYR of 
skeleta l mu cle, RYR I (90). A major breakthrough occuITed whe n the first mutation, 
R6 I 5C, was found to be assoc iated with porcine MHS, wh ich co-segregates with 
porcine MH phenotypes (9 1, 92). As porcine MH is associated onl y with the RYRJ 
R6 1 SC mutation, a molecular genetic test was developed to predict porcine MH 
susceptibility by detec ting this mutation within RYRJ (93) . 
1. 5.2 MH in other animals 
MH has also been found in the dog (94), and Roberts et al. (200 1) found a V547 A 
mutation within canine RYRJ which is linked to MH in dogs (95), although the 
homologous mutation has not been found in humans. MH is also found in the cat (96, 
97) and in the horse (98, 99), however molecular genetic studi es have not yet been 
performed in these animals. 
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1.6 Molecular genetics of human MH 
1.6.1 RYRl mutations 
As with porcine MH, linkage analysis has shown that RYRJ is a candidate gene 
associated with human MH and is located on chromosome I 9q ( I 00, 101 ). Later, an 
R614C mutation , homologous to porcine R61 SC, wa found in human RYR I . This 
mutation co-segregates with the IVCT phenotype in some MH susceptible families , and 
both homozygous and heterozygous mutations clearly match the phenotype (102). 
Hence, RYRJ is linked to MH and the heterozygou s mutation within the gene can lead to 
su ceptibility show ing an autosomal dominant trait for this di . order. To date, over 60 
mutations associated with MH and/or CCD have been found within RYR I (Table 1-1 ). A 
single-amino-acid deletion has also been reported to be associated with MH (103). 
RYRJ mutations found so far are clustered in specific region called "hot spots" -
N-terminal (exon 2-17), central ( exon 39-46) and C-termi nal (exon 95-102) (Figure 1-3 ). 
The N-tcrminal and central hot spots are located in the foot region of the RYR ex posed 
to the cytoplasm, and the C-terminal one is located in the channel region embedded in 
the SR membrane. 
1.6.2 Functional effects of RYRl mutations 
Cultured skeleta l muscle cell s from an MHS indi vidual show an abnormal response 
aga inst halothane, and a mutant skeletal muscle RYR containing RYR I mutations also 
leads to high sensitivity to drugs (69). HEK-293 cell s expressing the mutant RYR also 
show abnormal responses against drugs, although all mutations have not yet been 
investigated for their functional effect on the RYR (104. 105). Mutant RYR appears to 
be leaky resulting in higher resting Ca2+ concentrations in cytoplasm (106). Hence, 
causative mutations with in RYRJ may alter the RYR function as a calcium release 
channel. The difference of effect on RYR function between different mutations is still 
unclear. Some mutations, however appear to show higher sensitivity to drugs than do 
others (107). 
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Exon Nucleotide Amino acid Disorder Proportion Reference 
RYRI 6 C487T RI 63C M H, CCD 2% Quane et al. , 1993 (I 08) 
mutations 9 G742 A G248R MH 2% Gi llard et al., 1992 ( I 09) 
11 G I02 1A G34 1R MH 6% Quane et al ., 1994 ( I I 0) 
39 C6487T R2 I 63C MH 4% M anning et al., 1998 ( 111 ) 
39 G6502A V 2 168M MH 7% M anning et al., 1998 ( I 11) 
40 C66 17T T 2206M MH 3% M anni ng et al .. I 998 ( 111 ) 
45 G7303A G2434R MH 4% Keat ing et al. , 1994 ( I 12) 
100 C I4477T T 48261 MH I famil y Brown et al. , 2000 ( I 13) 
102 TI 4693C 14898T MH, CCD 4% Lynch et al., 1999 ( I 14) 
CACNA I S 26 G3256T RI086C MH I famil y Jurkat-Rott et al. , 2000 ( 115) 
mutations 26 G3257A R 1086H MH I family M onnier et al., 1997 ( l 16) 
Table 1-1 Selected RYRJ and CACNA JS mutations 
Over 60 mutations wi thin RYRJ have been reported to date, which are associated wi th 
MH and/or CCD. Onl y two mu tat ion s have been ident ifi ed within CA CNA IS from MHS 
indi viduals . These two mutat io ns are linked on ly to M H, and no CA CNA JS mutat ions 
are known to be associated with CCD. 
1.6. 3 Molecular genetic testing 
As RYRJ mutati ons clearl y co-segregate w ith MH susceptibility in some fa milies, 
molecul ar genetic testing may be usefu l to predict susceptibi lity instead of the IVCT for 
certain fa milies (1 17). It is possible to establi sh an MHS diagnosis by detecting a 
causat ive mutati on because MH indi viduals do not contain RYRJ mutations, and 
indi viduals with mutati ons are always MHS (11 8, 119). This doe not necessaril y mean, 
however that all MHS patients have RYRJ mutati ons. It has been reported that between 
30 and 80 % of MHS families show linkage to RYRI (120). In fac t, discordance 
between genotype and IVCT phenotype has been observed in some families (12 1, 122) . 
Hence, molecular genetic tes ting may be useful in some indi viduals in specific families, 
13 
but it cannot be suitable for all cases. It may be useful to use as a supplemental method 
for the IVCT in some specific families (123). 
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Figure 1-3 A linear representation of location of RYRJ mutations 
The RYR consists of 5,038 amino acids represented by a black line. Red arrows indicate 
the location of RYRI mutations found . They are clustered in N-terminal , central or 
C-terminal hot spots. Most hot-spot regions form the foot segment exposed in cytosol , 
and the C-terminal region is embedded in the SR membrane forming the transmembrane 
segment. 
1. 6. 4 Other susceptible loci to MH 
30-80 % linkage to RYRJ indicates genetic heterogeneity of MH (120). This means that 
there must be other candidate loci associated with MH. In fact, linkage studies have 
identified other candidate loci on several chromosomes. Robinson et al. (1997) have 
performed a genome-wide scan of a MHS family, which does not have linkage on 
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chromosome l 9q, encoding RYRJ (124). These authors found strong linkage between 
MHS and chromosome lq encoding the a-subunit of the DHPR. The gene (CACNA JS) 
was subsequentl y sc reened, and an Rl086H mutation was found to co-segregate with 
MH susceptibility in thi s fami ly (116). Later, a second mutation (Rl086C) was found 
within this gene indicating that the CACNA J S gene may be a second candidate locus 
(115), although the fun cti onal effect of CACNA JS mutati ons is still unclear. Other 
candidate loci have been demonstrated on chromosome 3q (125), Sp (124), 7q (l 26) and 
l 7q ( 127), however these are controversial because no mutations have been found 
within these loc i, and potential candidate genes have not been identified fo r some of 
them. 
1. 7 Research goals 
There were two separate and unrelated goa ls for the research described in thi s thes is. 
Both however, were aimed at identifying genet ic fac tors causing MH in New Zealand 
fa mili es. 
1. 7. 1 Screening RYRJ of the patient with exercise-induced MH 
Recentl y, a male New Zealander suffe red a fulminant MH crisis and died. The reaction 
was induced by exerci se, but he did not have any signs of MH before the crisis and he 
did not have a family hi story of MH. Furthermore, molecul ar genet ic analys is showed 
that he lacked RYRJ mutations previously identifi ed in ew Zealand fam ilies. It is well 
known that MH reactions can be triggered by exercise, and in fact, mutations have been 
fo und in patients who showed exerci se- induced MH-like reactions (128) . It has not been 
confirmed, however that specific RYRJ mutations are responsible for exerci se-induced 
MH. It was poss ible that thi s patient had a novel RYRJ mutation that is responsible for 
MH susceptibility caused by excess exercise. To determine thi s possibility, mRNA of 
the patient was extracted from his skeletal muscle followed by production of cDNA 
from mRNA usi ng reverse transcriptase (RT). DNA fragments were amplified by PCR 
covering the entire RYRJ cDNA. The fragments were purified and directly sequenced to 
detect any mutations and polymorphisms. 
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1. 7.2 Linkage analysis within the CH family 
To date, over 40 MH fa mili es have been identified in New Zealand. One of the la rges t 
MH fa mili es identifi ed as the CH famil y has more than 1,400 indi viduals in tota l. 
Linkage analys is has shown that RYRJ is responsible fo r MH uscepti bility in thi s 
fa mil y (129), and in fac t, the T48261 mutati o n in MHS pati ents was fo und to 
co-segregate with the phenotype in thi s fa mil y (1 I 3) . It has a lso been observed , however 
that there is some di scordance between genotype and phe notype showing th at some 
MHS pati ents, as di agnosed by the IVCT do not have the T48261 mutati on. Although 
the fVCT can produce fa lse d iagnoses, the rate of di scordance in thi s fa mil y is hi gher 
than the probability of lYCT fa lse di agnos is. Hence, it is tho ught that MH suscepti b ility 
in thi s fa mil y is not caused o nl y by RYRJ , bu t also by one or other tra its in the 
di scordant pati ents because of heterogeneity of MH . To search fo r other candidate loc i 
th at are susceptible to MH, a genome-wide scan was perfo rmed fo r pati ents selected 
fro m the C H fa mil y. Twent y-s ix indi viduals were selected from the fa mil y, and 
no n-parametric analys is was adopted fo r the linkage analys is. 
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